Last reviewed · How we verify
Kanacin (KANAMYCIN)
Kanamycin, also known as Kanacin, is a small molecule aminoglycoside antibacterial drug that targets the gap junction beta-2 protein. It was originally developed by Apothec, and its current owner is also Apothec. Kanamycin was FDA-approved in 1973 for various bacterial infections, including pneumonia, septicemia, and skin infections. The drug has a low bioavailability of 1% and a half-life of 2.1 hours. Kanamycin is available as a generic medication, with 11 generic manufacturers, and is off-patent.
At a glance
| Generic name | KANAMYCIN |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Aminoglycoside Antibacterial |
| Target | Gap junction beta-2 protein |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Bacterial pneumonia
- Bacterial septicemia
- Burn Wound Infections
- Cholangitis
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disease of abdomen
- Infectious disorder of joint
- Meningitis
- Preoperative Bowel Preparation
- Urinary tract infectious disease
Common side effects
Drug interactions
- metocurine
- mivacurium
- pancuronium
- pipecuronium
- rocuronium
- suxamethonium
- torsemide
- tubocurarine
- vecuronium
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Acute Application of Antibiotic Powder in Open Fracture Wounds (PHASE4)
- Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
- Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia (PHASE4)
- Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) (NA)
- Tobradex as Intracanal Medicament (NA)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kanacin CI brief — competitive landscape report
- Kanacin updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI